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Introduction
Th   irteen original articles focusing on shock were 
published in Critical Care in 2009. Two papers concen-
trated on the pathophysiology of heart dysfunction and 
its response to standard therapeutic interventions, and 
three other studies concentrated on the role of pharma-
cological inhibition of the sympathetic central nervous 
system during sepsis using either central sympatholytics 
or thoracic epidural blockade. Five articles concentrated 
on the (side) eﬀ  ects of arginine vasopressin and its analog 
terlipressin on the heart and the visceral organs, and on 
the question of which type of solution ﬂ   uid is most 
appropriate for ﬂ   uid resuscitation. Th  ree ﬁ  nal  studies 
investigated the pharmacological interventions in experi-
mental models of acute respiratory distress syndrome 
(ARDS). Th   e present review summarizes the key results 
of these studies and discusses them in the context of the 
relevant scientiﬁ  c and clinical background, in particular 
highlighting the relation to studies published in this 
journal as well as in other journals during this period.
Pathophysiology of heart function
By deﬁ  nition, septic shock comprises systemic vasodila-
ta  tion and consecutive arterial hypotension despite 
increased cardiac output. Approximately 40% of these 
patients also develop myocardial dysfunction, which is 
characterized by reduced systolic contractility, impaired 
diastolic relaxation and – in some patients – ventricular 
dilatation [1,2]. Since aggressive ﬂ  uid resuscitation is one 
of the cornerstones of the hemodynamic management of 
patients with septic shock, diastolic dysfunction may 
assume particular importance. Th  e  frequency-dependent 
acceleration of relaxation is one of the physiological 
mechanisms to maintain adequate ventricular ﬁ  lling at 
increased heart rates, and therefore Joulin and colleagues 
tested the hypothesis of whether endotoxin (lipopoly-
saccharide) may impair the cardiac force–frequency 
relationship [3]. In cardiomyocytes in vitro, as well as in 
an ex vivo isolated heart preparation, lipopolysaccharide 
blunted the otherwise marked drop in the diastolic time 
constant.  In vivo, echocardiography showed a reduced 
early diastolic mitral annulus velocity, suggestive of 
impaired left ventricular diastolic relaxation. Disturbed 
sarcoplasmatic Ca2+ homoeostasis and increased serine/
threonine phospatase activity were responsible for this 
diastolic dysfunction. Th  e authors concluded that the 
disruption of this funda  mental mechanism ensuring 
adequate cardiac ﬁ  lling may be particularly detrimental 
during septic shock, which is commonly associated with 
tachycardia and dependence on increased preload.
Th   e article by Joulin and colleagues was accompanied 
by an editorial commentary from Heitner and Hollenberg 
highlighting the importance of the sarcoplasmic reticu-
lum Ca2+-ATPase in this context, and at the same time 
emphasizing that there are also other important media-
tors of adequate diastolic function [4]; for example, nitric 
oxide (NO) [2]. In fact, in a murine model of well-
resuscitated septic shock resulting from cecal ligation 
and puncture (CLP)-induced peritonitis, Barth and 
colleagues showed that both genetic deletion and 
selective pharmacologic blockade of the inducible 
isoform of the NO synthase (iNOS, NOS2) was asso-
ciated with markedly improved systolic contraction and 
catecholamine responsiveness, but simultaneously deteri-
or  ated diastolic relaxation [5]. Furthermore, Bougaki and 
colleagues most recently demonstrated the crucial role of 
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the maintenance of heart function in sepsis: colon 
ascendens stent peritonitis-induced septic shock caused 
a more pronounced depression of both systolic contrac-
tion and diastolic relaxation in NOS3-knockout mice 
than in the wild-type strain [6].
Sedation is frequently necessary in patients with septic 
shock, and therefore Zausig and colleagues investigated 
the eﬀ  ects of dose-dependent eﬀ  ects of various induction 
agents (propofol, midazolam, s(+)-ketamine, methohexi-
tone, etomidate) in a Langendorﬀ   heart preparation from 
rats rendered septic by CLP [7]. Propofol exerted the 
most pronounced depressant eﬀ  ects on both the maximal 
systolic contraction and the minimal diastolic relaxation, 
and cardiac work. Furthermore, propofol only adversely 
deleteriously aﬀ   ected the myocardial oxygen supply–
demand ratio. In contrast, s(+)-ketamine was associated 
with the best maintenance of cardiac function. Within 
the limits of the study – that is, the use of an ex vivo 
isolated organ model – the authors concluded that s(+)-
ketamine may be an alternative to the comparably inert 
etomidate, the use of which is, however, limited due to its 
endocrine side eﬀ  ects [8].
Th   e study by Zausig and colleagues was accompanied 
by an editorial commentary from Royse highlighting 
both the merits as well as the pitfalls of the study [9]; for 
example, the lack of an analysis of the eﬀ  ects of volatile 
anesthetics, which are known to promote protective 
preconditioning during conditions of ischemia–reper  fu-
sion, particularly in the heart. Most recently, the study by 
Zausig and colleagues on induction agents was 
complemented by the analysis of the eﬀ   ects of the 
inotropes dobutamine, dopamine, epinephrine, and 
levosimendan in the same model, thus giving an overview 
of the cardiac eﬀ  ects of drugs most commonly used for 
the management of patients with septic shock [10].
The sympathetic central nervous system in sepsis
Th  e autonomic nervous system is referred to as an 
important regulator of the immune system due to its 
capacity for modulating the production of proinﬂ  am  ma-
tory cytokines by immune cells. While catecholamines 
exhibit a friend and foe character [11], acetylcholine – 
the key mediator of the cholinergic anti-inﬂ  ammatory 
pathway – can directly inhibit cytokine activation via the 
α7 subunit of the nicotinic acetylcholine receptor 
expressed on macrophages, and thus can dampen the 
inﬂ  ammatory response [12].
Administration of central α2-agonists allows lowering 
sympathetic tone due to stimulation of central α2-
receptors and consecutive inhibition of noradrenergic 
neurotransmission in the medulla oblongata. As a logical 
consequence of a previous experiment using cholines-
terase inhibition with physostigmine [13], Hofer and 
colleagues investigated the eﬀ   ect of the central α2-
receptors clonidine and dexmedetomidine in a murine 
model of CLP-induced sepsis [14]. Both drugs improved 
survival, which was associated by a markedly attenuated 
release of the proinﬂ  ammatory cytokines IL-1β, IL-6 and 
TNFα as well as reduced activation of the nuclear 
transcription factor NF-κB. Since clonidine did not aﬀ  ect 
cytokine release in blood stimulated with lipopoly-
saccharide ex vivo, the central nervous eﬀ  ect was respon-
sible for its beneﬁ   cial properties. It is noteworthy, 
however, that this protective eﬀ  ect was only present after 
pre-emptive drug injection (that is, using a pretreatment 
design), whereas drug administration as early as 1 hour 
after induction of CLP had no eﬀ  ect. Th  e  accompanying 
editorial comment from Ulloa and Deitch [15] empha-
sized this issue as a putative consequence of high concen-
trations of circulating catecholamines that can boost the 
initial inﬂ  ammatory response during the early phase of 
sepsis, the possibly confounding role of keta  mine anes-
thesia as well as the lacking antibiotic treat  ment in the 
model by Hofer and colleagues.
Th  oracic epidural anesthesia (TEA) using local anes-
thetic is associated with regional sympathetic block  ade. 
Two complementary studies by Lauer and colleagues and 
by Freise and colleagues therefore respectively addressed 
the question of whether TEA may beneﬁ  cially inﬂ  uence 
the pulmonary microcirculatory perfusion [16] and 
hepatic microcirculatory perfusion [17] in rats with CLP-
induced sepsis. To diﬀ  erentiate between hyperdynamic 
and hypo  dynamic sepsis, Lauer and colleagues assessed 
the eﬀ  ects of TEA both 6 and 24 hours after the CLP 
procedure. Finally, an isolated lung preparation allowed 
the authors to clarify the mechanisms of a possible impact 
of TEA on pulmonary endothelial dysfunction. TEA 
exerted marked anti-inﬂ  ammatory properties by reducing 
the amount of exhaled NO during both hyperdynamic 
and hypo  dy  namic sepsis and, moreover, reduced 
neutrophil inﬂ   ux into the lungs in the hypodynamic 
phase. Interestingly, this anti-inﬂ  ammatory eﬀ  ect reduced 
endothelial dys  function only during hyperdynamic sepsis, 
whereas it even aggravated endothelial function in the 
hypodynamic phase [16]. In addition, Freise and 
colleagues showed that TEA normalized the sepsis-
related hepatic sinusoidal blood ﬂ  ow, most probably as a 
result of a restoration of the otherwise impaired hepatic 
arterial buﬀ  er response, and ameliorated the leukocyte 
adhesion to the endothelium [17]. Th  e two articles 
represent the logic consequence of previous experiments 
by the authors’ group both in rodents [18,19] and in sheep 
[20], and thus add further pieces to the puzzling debate 
on the use of TEA during sepsis. Clearly, there is 
traditional reluctance against this approach [21], but the 
existing experimental data [22,23] and clinical data [24] 
should foster its thorough evaluation.
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Vasopressin and terlipressin
Despite the lack of improvement for mortality in the 
Vasopressin in Septic Shock Trial (VASST) study [25], 
and although worsened mortality and morbidity were 
recently reported in children [26] and in trauma patients 
[27], arginine vasopressin (AVP) and its analog terli-
pressin are increasingly used to restore blood pressure 
during vasodilatory shock. Th   e increase in blood pressure 
is mainly due to systemic vasoconstriction, and thus may 
lead to a drop in coronary blood ﬂ  ow despite increased 
coronary perfusion pressure. Th   ese drugs, despite some 
encouraging data in patients with cardiogenic shock [28], 
may therefore carry the risk of inducing myocardial 
ischemia in patients with underlying cardiac pathology. 
In fact, the VASST study explicitly excluded patients with 
cardiogenic shock, congestive heart failure, and unstable 
coronary artery disease.
Consequently, Indrambarya and colleagues compared a 
72-hour infusion of AVP (infusion rate equivalent to 
0.04  IU/minute in a 70 kg human being), dobutamine 
(8.33 μg/kg/minute) and vehicle in a murine model of 
cardiac ischemia [29]. At day 1 and day 3 after coronary 
ischemia, echocardiography demonstrated a more pro-
nounced fall in left ventricular ejection fraction than in 
the vehicle-treated and dobutamine-treated animals, 
which ultimately coincidence with a nearly doubled 
mortality in the AVP group. Th   e authors attributed this 
higher mortality to sudden cardiac arrhythmias caused 
by the KATP-channel blocking properties of AVP, and 
concluded that the use of AVP should be cautioned in 
patients with underlying cardiac disease.
Th  e accompanying editorial highlighted the complex 
eﬀ  ects of AVP on cardiac function, which relate to both 
direct and indirect mechanisms [30]. In fact, AVP 
markedly decreased systolic contractility in swine after 
transient myocardial ischemia in a dose-dependent 
manner [31] as a result of a coronary vasoconstriction-
related reduction in coronary ﬂ  ow [31,32] that ultimately 
led to myocardial ischemia. Weig and colleagues showed 
enhanced cardiac con  tract  ility after vasopressin receptor 
2 gene transfer [33], however, and Ryckwaert and 
colleagues demonstrated that the terlipressin-induced 
coronary hypoperfusion was only present under constant 
pressure, not under constant ﬂ   ow conditions [34]. 
Moreover, Simon and colleagues compared AVP with a 
standard treatment with noradrenaline during long-term, 
resuscitated porcine fecal peritonitis-induced septic 
shock, and AVP attenu  ated the otherwise progressive 
increase in troponin I [35]. In their study, AVP also 
compared favorably with noradrenaline with respect to 
liver injury and, in particular, renal function. Again, 
nothing is simple and easy when transferring 
experimental ﬁ   ndings to the clinical setting. While 
Gordon and colleagues most recently reported in a post 
hoc analysis of the VASST study that AVP reduced 
progression to renal failure in patients with septic shock 
and acute kidney injury [36], other authors have shown 
that vasopressin impaired intestinal mucosal perfusion 
and renal oxygenation after cardiac surgery [37,38].
Although both AVP and terlipressin exert vasopressor 
properties, distinct pharmacokinetic diﬀ  erences as well 
as pharmacodynamic diﬀ   erences between these two 
drugs must be taken into account: the half-life of 
terlipressin is 4 to 6 hours (vs. 20 minutes for AVP), and 
it has a nearly threefold higher selectivity for the vaso-
pressin receptor 1a, which might theoretically result in 
less vasopressin receptor 2-mediated side eﬀ  ects  (for 
example, anti-diuresis and activation of coagulation) [39]. 
Morelli and colleagues therefore performed the Continu  ous 
Terlipressin Versus Vasopressin study, the ﬁ  rst clinical 
study to compare the eﬀ  ects of continuous intravenous 
AVP (0.03 IU/minute) and terlipressin (1.3 μg/kg/hour; 
that is, approximately 2.5  mg/day) with noradrenaline 
(15 μg/minute) in the control arm (n = 15 in each group) 
[40]. In addition to these ﬁ  xed infusion rates, all patients 
received open-label noradrenaline as needed to achieve 
the target blood pressure of 70 ± 5 mmHg. Whereas terli-
pressin allowed for a much more pronounced reduction 
in open-label noradrenaline requirements, none of the 
parameters of hemodynamics, gas exchange, metabolism 
or organ function showed any signiﬁ  cant  intergroup 
diﬀ  erence [40].
Th   e editorials accompanying the studies by Simon and 
colleagues and by Morelli and colleagues emphasized the 
possible limitation of these investigations related to the 
use of ﬁ  xed doses of the drugs that are supplemented by 
noradrenaline, and furthermore highlighted the potential 
of AVP or terlipressin as a ﬁ  rst-line vasopressor rather 
than as a last-resort therapy [41,42]. In this context, the 
study by Rehberg and colleagues on the use of AVP and 
terlipressin in ovine septic shock induced by fecal 
peritonitis assumes particular importance: terlipressin 
but not AVP was associated with less ﬂ  uid requirements 
to maintain constant hematocrit levels, and ultimately 
prolonged survival [43]. Th  e concept of using AVP or 
terlipressin is also of interest when taking into account 
the results of the VASST study: in fact, despite an overall 
comparable outcome, the mortality in patients with less 
severe septic shock was signiﬁ  cantly lower in the vaso-
pressin group than in the noradrenaline control group 
[25], suggesting that an early intervention with 
noncatecholaminergic vasopressors may increase 
survival from septic shock.
Fluid resuscitation
Fluid resuscitation is one of the cornerstones of the treat-
ment of patients in the intensive care unit, particularly 
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injury [44], and safety issues of the solutions used there-
fore assume major importance. It is well established that 
hydroxyethyl starch (HES) can induce kidney injury 
[45,46], but it is still a matter of debate whether the 
various HES preparations have diﬀ  erent  nephrotoxic 
properties [47,48]. Even clinical studies have yielded 
equivocal results: a third-generation balanced 6% HES 
130/0.42 plus crystalloid solution was associated with 
less acidosis, systemic inﬂ  ammation and lower neutrophil 
gelatinase-associated lipocalin blood concentrations than 
a nonbalanced HES solution combined with saline [49]; 
and the incidence of acute kidney injury was similar in 
surgical intensive care unit patients receiving a pre  domi-
nantly HES-based or gelatin-based ﬂ  uid therapy [50].
Hüter and colleagues therefore compared a second 
HES preparation (10% HES 200/0.5) and 6% HES 
130/0.42 with a balanced crystalloid solution in a porcine 
isolated renal perfusion model [51]. After hemodilution 
in vivo, the glomerular ﬁ  ltration pressure and creatinine 
clearance were higher in the crystalloid control group. 
Th   e 10% 200/0.5 HES solution caused a more severe drop 
in creatinine clearance than the third-generation 
prepara  tion, which was associated with more pronounced 
macro phage  inﬁ  ltration and tubular damage. Th  is latter 
eﬀ  ect was independent of the ﬁ  ltration pressure, which 
was identical in the two HES groups. Most recently, 
Schick and colleagues conﬁ   rmed these nephrotoxic 
properties of HES in rats with CLP-induced sepsis: 
despite a signiﬁ  cantly higher cardiac output, HES and 
gelatine were associated with a more severe histological 
tissue injury and higher neutrophil gelatinase-associated 
lipocalin serum levels than treatment with normal saline 
or balanced crystalloid solutions [52]. Th  ese results 
conﬁ  rm the warnings raised in a recent review on this 
topic [53].
An accompanying editorial highlighted the fact that 
third-generation HES preparations may lead to com-
parable kidney injury as older compounds [54]. In the 
absence of large randomized, controlled clinical trials, 
doubts on the safety of HES therefore remain due to the 
evidence that certain colloids, particularly in high 
amounts, may cause harm in diﬀ  erent organ systems. 
Furthermore, despite the ongoing debate on the optimal 
solution for ﬂ  uid for resuscitation, there is little to no 
evidence that colloids improve outcome in critically ill 
patients, and thousands of patients included in random-
ized controlled trials have been safely resuscitated using 
only crystalloids [55].
Nevertheless, Hiltebrand and colleagues showed that, 
after major abdominal surgery in pigs, goal-directed 
therapy (targeting a mixed venous hemoglobin oxygen 
saturation >60%) combining lactated Ringer’s solution 
(3  ml/kg/hour) with HES boluses compared favorably 
with lactated Ringer’s solution alone in restoring 
mesenteric microcirculation and macrocirculation and 
metabolism  [56]. It is noteworthy, however, that the 
parameters of intestinal metabolism (mesenteric acid–
base status, lactate levels) did not show major beneﬁ  t. 
Furthermore, the authors’ experiments comprised an 
observation period of only 4 hours, and data on perfusion 
or renal function were not recorded. Th  e study by 
Hiltebrand and colleagues emphasizes the crucial 
importance of the underlying pathology: in pigs 
challenged with endotoxin or rendered septic by fecal 
peritonitis, a high-volume ﬂ  uid resuscitation (15 ml/kg/
hour Ringer’s lactate plus 5 ml/kg/hour HES) increased 
mortality despite a better initial hemodynamic stability 
when compared with a moderate-volume approach 
(10 ml/kg/hour Ringer’s lactate) [57].
Finally, in a porcine model of short-term, partially 
resuscitated hemorrhagic shock, Phillips and colleagues 
demonstrated without using colloids that the type of 
crystalloid solution used assumes particular importance: 
when compared with normal saline, lactated Ringer’s 
solution improved the extravascular lung water, acid–
base status and mean arterial blood pressure, but not 
oxygenation, when the total amount of ﬂ   uid did not 
exceed 250 ml/kg [58]. Th  e authors tried to mimic the 
prehospital and early clinical resuscitation phase of 
hemorrhagic shock and resuscitation, which may explain 
the discrepancy from the data reported by van der 
Heijden and colleagues: these authors did not ﬁ  nd any 
diﬀ  erence in extravascular lung water or the lung injury 
score after 90 minutes of ﬂ  uid loading for hypovolemia 
with NaCl 0.9%, gelatin 4%, HES 6%, or albumin 5%, no 
matter whether the patients were septic or not [59].
Pharmacological interventions in experimental 
ARDS
Th  ere is ample experimental evidence that β2-agonists 
may represent an adjunct therapy in the management of 
ARDS due to reduced pulmonary neutrophil seques-
tration and activation, increased alveolar ﬂ  uid clearance, 
enhanced surfactant secretion, and modulation of the 
inﬂ  ammatory and coagulation cascade [60]. Moreover, 
the recent Beta-Agonist in Acute Lung Injury Trial on 
the eﬀ   ects of intravenous 15 μg/kg/hour salbutamol 
showed a signiﬁ  cant decrease in extravascular lung water 
and airway plateau pressure in the treatment group at 
day 7, which ultimately resulted in a trend towards lower 
Murray ARDS scores [61] – one of the mechanisms being 
the upregulation of matrix metalloproteinase-9 in type II 
alveolar cells [62]. Except for a slightly higher incidence 
of new-onset supraventricular arrhythmia, the treatment 
was well tolerated. By contrast, the Albuterol for the 
Treatment of ALI Trial did not show signiﬁ  cant improve-
ment of ventilator-free days or mortality [63]. Th  ese 
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vascular side eﬀ   ects of β2-agonists; for example, an 
increased cardiac output.
Th   is question of the role of β2-agonists was addressed 
by Briot and colleagues [64], who measured the time-
course of capillary-alveolar leakage of macromolecules 
(ﬂ  uorescein-labeled dextran) in a canine model of oleic 
acid-induced acute lung injury. Oleic acid increased the 
capillary-alveolar leakage, and infusing terbutaline 
infusion further enhanced the macromolecule leakage, 
which coincided with signiﬁ   cantly increased cardiac 
output and pulmo  nary artery pressure. Th  e authors 
speculated that the increased blood ﬂ  ow  caused 
recruitment of leaky pulmo  nary capillaries, which in turn 
would aggravate overall lung endothelial permeability. 
Th  ese ﬁ   ndings agree with data from Schreiber and 
colleagues demonstrating that a dobutamine-induced 
increase in pulmonary blood ﬂ  ow in rats with unilateral, 
left lung acid instillation increased lung edema as well as 
inﬂ   ammatory cell inﬁ   ltration and histopathologic 
damage in the contralateral, unaﬀ   ected organ [65]. 
Consequently, the question of the role of β2-agonists in 
ARDS remains unanswered [63].
Th   e accompanying editorial comment emphasized one 
of the most important issues in this context: pharmaco-
logical monotherapy is unlikely to simultaneously address 
the various interactions between diﬀ  erent pathophysio-
logical pathways in ARDS [66]. Th   is phenomenon might 
also limit the use of recombinant human activated 
protein C (rhAPC) for the treatment of ARDS. While 
there is ample evidence from large animal models that 
infusing rhAPC can improve lung function and attenuate 
morphological organ injury [67-71] as a result of reduced 
tissue inﬂ   ammation and oxidative stress [72], a 
randomized clinical trial in patients with acute lung 
injury failed to show any beneﬁ  t of this treatment [73]. 
Th   e latter study was limited to patients with acute lung 
injury rather than ARDS, and hence to patients with a 
reduced risk of bleeding.
Since intravenous rhAPC is known to increase bleeding 
complications, Waerhaug and colleagues tested the 
hypothesis of whether aerosolized rhAPC might improve 
lung function in their well-established model of oleic 
acid-induced ovine acute lung injury [74]. Inhaled rhAPC 
improved arterial oxygen partial pressure as a result of 
reduced intrapulmonary shunt perfusion, which was 
associated with signiﬁ   cantly larger volumes of aerated 
lung tissue. Inhaled rhAPC did not, however, prevent the 
increase in extravascular lung water nor the 
lipopolysaccharide-induced acute pulmonary hyperten-
sion [74]. Nevertheless, the ﬁ  ndings by Waerhaug and 
colleagues are complementary to data reported by 
Finigan and colleagues: treatment with intravenous 
rhAPC started either before or at 30 and 150 minutes 
after initiating injurious mechanical ventilation (tidal 
volume, 20 ml/kg) in mice marked attenuated pulmonary 
vascular leakage [75]. Finally, Maniatis and colleagues 
demonstrated most recently that inhaled rhAPC is 
equally eﬀ   ective under these conditions [76]. In the 
accompanying editorial, Liu and colleagues emphasized 
the potential value of this innovative approach for the use 
of rhAPC, but also highlighted the fact that the response 
of arterial oxygen partial pressure  to therapeutic 
interventions is not related to mortality of ARDS and, 
hence, the question of whether inhaled rhAPC may 
improve outcome in these patients remains open [77].
Nosocomial infection with methicillin-resistant 
Staphy lo coccus  aureus (MRSA) represents a particular 
problem in intensive care units, both due to the budget 
and personnel burden [78] as well as due to the 
epidemiology and virulence of the bacterial strain [79]. 
Enkehbaater and colleagues therefore established a novel 
ovine model of MRSA-induced ARDS, which results 
from a double-hit challenge comprising smoke injury and 
MRSA installation into the airways [80] and is charac  ter-
ized by circulatory collapse and vascular hyperpermea-
bility [81].
Excess NO production and formation of reactive 
nitrogen species (for example, peroxynitrite) are attri-
buted to assume crucial importance in the pathophysio-
logy of ARDS [82]. Jonkam and colleagues therefore 
tested the hypothesis of whether excess NO and/or 
reactive oxygen species production is also responsible for 
the lung injury induced by MRSA pneumonia [83]. In 
fact, after smoke injury and instillation of MRSA, ewes 
showed markedly increased tissue expression of both 
iNOS and endothelial NO synthase, which was associated 
with signiﬁ   cantly higher blood nitrate and nitrite 
concentrations. In addi  tion, the tissue polyADP ribose 
levels were signiﬁ  cantly elevated. In this context, a most 
recent article by Su and colleagues deserves particular 
attention: in an ovine model of fecal peritonitis-induced 
septic shock, these authors compared a highly iNOS-
selective NO synthase blocker with noradrenaline and 
the combination of these two compounds. Both with or 
without additional nor  adrena  line, animals treated with 
the selective iNOS blocker showed less pulmonary artery 
hypertension and gas exchange impairment and higher 
visceral organ blood ﬂ   ow [84]. Taken together, the 
ﬁ  ndings in these clinically relevant large animal models 
raise again the question of (selective) iNOS inhibition in 
sepsis [85,86].
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